

Amendments To The Claims

1-20. (Canceled).

21. (Currently amended) A chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence encoded by the nucleic acid sequence in ~~SEQ ID NO:6~~ SEQ ID NO:3 and a variable heavy chain encoded by the nucleic acid sequence in ~~SEQ ID NO:9~~ SEQ ID NO:5.

22. (Currently amended) An anti-CD20 variable light chain encoded by the nucleic acid sequence in ~~SEQ ID NO:6~~ SEQ ID NO:3.

23. (Currently amended) An anti-CD20 variable heavy chain encoded by the nucleic acid sequence in ~~SEQ ID NO:9~~ SEQ ID NO:5.

24. (Currently amended) A chimeric anti-CD20 antibody having a variable light chain encoded by the nucleic acid sequence in ~~SEQ ID NO:6~~ SEQ ID NO:3.

25. (Currently amended) A chimeric anti-CD20 antibody having a variable heavy chain encoded by the nucleic acid sequence in ~~SEQ ID NO:9~~ SEQ ID NO:5.

26. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.

27. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 which is an IgG1.

28. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 which is an IgG1.

29. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 which comprises a radiolabel.

30. (Previously presented) The chimeric anti-CD20 antibody of Claim 29 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

31. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 wherein said radiolabel is attached to the antibody via a chelate.

32. (Previously presented) The chimeric anti-CD20 antibody of the Claim 31 wherein the chelate is MX-DTPA.

33. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 which comprises a radiolabel.

34. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

35. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 wherein said radiolabel is attached to the antibody via a chelate.

36. (Previously presented) The chimeric anti-CD20 antibody of the Claim 24 wherein the chelate is MX-DTPA.

37. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 which comprises a radiolabel.

38. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

39. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 wherein said radiolabel is attached to the antibody via a chelate.

40. (Previously presented) The chimeric anti-CD20 antibody of the Claim 25 wherein the chelate is MX-DTPA.

41. (Previously presented) A pharmaceutical composition comprising a chimeric anti-CD20 antibody according to Claim 21 and a pharmaceutically acceptable carrier.

42. (Previously presented) An imaging composition comprising a chimeric anti-CD20 antibody according to Claim 21 and an acceptable carrier.

43. (Previously presented) The pharmaceutical composition of Claim 41 which comprises a radiolabel.

44. (Previously presented) The imaging composition of Claim 42 which comprises a radiolabel.

45. (Previously presented) The pharmaceutical composition of Claim 43 wherein said radiolabel is yttrium (90) or iodine (131).

46. (Previously presented) The imaging composition of Claim 44 wherein said radiolabel is indium (111).

47. (Previously presented) The pharmaceutical composition of Claim 41 which is suitable for parenteral administration.

48. (Previously presented) The pharmaceutical composition of Claim 47 wherein parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous.

49. (Previously presented) The imaging composition of Claim 42 which is suitable for parenteral administration.

50. (Previously presented) The imaging composition of Claim 49 wherein parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous.

51. (Previously presented) The pharmaceutical composition of Claim 41 which delivers an effective dosage ranging from about 0.01 to 30 mg/kg body weight.

52. (Previously presented) The pharmaceutical composition of Claim 51 wherein said dosage ranges from about 0.01 to about 25 mg/kg body weight.

53. (Previously presented) The pharmaceutical composition of Claim 51 wherein said dosage ranges from about 0.4 mg to about 20.0 mg/kg body weight.

54. (Previously presented) The imaging composition of Claim 42 which delivers a dosage of radiation ranging from about 1 to 10 mCi.

55. (Previously presented) The imaging composition of Claim 54 wherein the radiolabel is indium (111).

56. (Previously presented) The imaging composition of Claim 55 wherein the dosage of radiation is about 5 mCi.

57. (Previously presented) The pharmaceutical composition of Claim 43 which is non-myeloablative.

58. (Currently amended) An anti-CD20 antibody comprising a variable light chain encoded by the nucleic acid sequence in ~~SEQ ID NO:6~~ SEQ ID NO:3.

59. (Previously presented) The anti-CD20 antibody of Claim 58 wherein said antibody is murine.

60. (Previously presented) The anti-CD20 antibody of Claim 59 further comprising a radiolabel.

61. (Previously presented) The anti-CD20 antibody of Claim 60 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (111), and iodine (131).

62. (Previously presented) The anti-CD20 antibody of Claim 61 wherein said radiolabel is yttrium (90).

63. (Currently amended) An anti-CD20 antibody comprising a variable heavy chain encoded by the nucleic acid sequence in ~~SEQ ID NO:9~~ SEQ ID NO:5.

64. (Previously presented) The anti-CD20 antibody of Claim 63 wherein said antibody is murine.

65. (Previously presented) The anti-CD20 antibody of Claim 63 further comprising a radiolabel.

66. (Previously presented) The anti-CD20 antibody of Claim 64 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (111), and iodine (131).

67. (Previously presented) The anti-CD20 antibody of Claim 65 wherein said radiolabel is yttrium (90).